Neuroendocrine tumour

6 trials 2 recruiting MedDRA PT
6 Registered trials
2 Recruiting
5 Unique sponsors
8 Unique IMPs
5 Commercial trials
Drug classes (ATC)
V Various (ATC V) 4
H Endocrinology (ATC H) 1
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 6 substances
Radiopharmaceutical 2 substances
Phase III: 2 Phase II: 1 Phase IV: 2 Phase I (Other): 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

2 trials
  • Advanced Accelerator Applications Commercial
    L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; LUTETIUM (177LU) OXODOTREOTIDE; OCTREOTIDE
    2023-507443-10-00 5 countries 2019 n=90 Orphan
    Ended
  • Voxel S.A. Commercial
    COPPER (64CU) CHLORIDE; EDOTREOTIDE; GALLIUM (68GA) CHLORIDE
    2025-524050-34-01 1 country n=80
    Not authorised

Phase II

1 trial
  • Advanced Accelerator Applications Commercial
    L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; LUTETIUM (177LU) OXODOTREOTIDE
    2023-507444-37-00 3 countries 2021 n=5 Orphan
    Ended

Phase IV

2 trials
  • Ariceum Therapeutics GmbH Commercial
    SATOREOTIDE TETRAXETAN LUTETIUM-177, SATOREOTIDE TETRAXETAN
    2024-515071-35-00 1 country 2022 n=3 Orphan
    Ended
  • Antwerp University Hospital Academic
    IMP not specified
    2022-502703-30-00 2 countries 2023 n=270
    Recruiting

Phase I (Other)

1 trial
  • ITM Solucin GmbH Commercial
    L-LYSINE HYDROCHLORIDE, L-ARGININE HYDROCHLORIDE; LUTETIUM (177LU) EDOTREOTIDE
    2024-512831-66-00 3 countries 2025 n=16 Orphan
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Advanced Accelerator Applications Commercial 2 Phase II, Phase III 0
ITM Solucin GmbH Commercial 1 Phase I (Other) 1
Voxel S.A. Commercial 1 Phase III 0
Ariceum Therapeutics GmbH Commercial 1 Phase IV 0
Antwerp University Hospital Academic 1 Phase IV 1
New trials by year
2019
1
2021
1
2022
1
2023
1
2025
1
← All indication landscapes